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Abstract
Background: The correct clinical staging of soft tissue sarcomas (STS) is critical for the selection of treatments. The
staging system consists of histological grade of the tumors and French Federation of Cancer Center (FNCLCC) system
based on mitotic count is widely used for the grading. In this study, we compared the validity and usefulness of Ki-67
grading system with FNCLCC system in JCOG0304 trial which investigated the efficacy and safety of perioperative
chemotherapy with doxorubicin and ifosfamide for STS.
Methods: All 70 eligible patients with STS in the extremities treated by perioperative chemotherapy in JCOG0304
were analyzed. Univariate and multivariate Cox regression analyses were conducted to investigate an influence
on overall survival.
Results: The reproducibility of Ki-67 grading system in the histological grading of STS was higher than FNCLCC
system (κ = 0.54 [95 % CI 0.39–0.71], and 0.46 [0.32–0.62], respectively). Although FNCLCC grade was not associated
with overall survival (OS) in univariate analysis (HR 2.80 [0.74–10.55], p = 0.13), Ki-67 grading system had a tendency to
associate with OS in univariate analysis (HR 4.12 [0.89–19.09], p = 0.07) and multivariate analysis with backward
elimination (HR 3.51 [0.75–16.36], p = 0.11).
Conclusions: This is the first report demonstrating the efficacy of Ki-67 grading system for the patients with STS in the
prospective trial. The results indicate that Ki-67 grading system might be useful for the evaluation of histological grade
of STS.
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Background
Soft tissue sarcomas (STS) in adults are rare malignant tu-
mors, and the incidence of STS is approximately 1 % of all
malignant tumors. According to the Soft Tissue Tumor
Registry reported by the Musculoskeletal Tumor Commit-
tee of the Japanese Orthopaedic Association, only 1540
cases of STS were registered in 2012 in Japan [1].
The prognosis and standard treatments of STS differ
in the clinical stages of the tumor. The American Joint
Committee on Cancer (AJCC)/International Union
against Cancer (UICC) staging system is the most widely
used for the staging of STS [2]. Surgical resection of the
tumor with or without radiotherapy is the standard
treatment and highly successful for stage I and II STS,
and systemic chemotherapy with doxorubicin (DOX)-
based regimen is standard for stage IV STS [3]. The
standard therapeutic modality for stage III STS is mainly
surgical resection; however, systemic perioperative
chemotherapy with DOX plus ifosfamide (IFO) is also
the promising treatment for high-risk STS [4]. There-
fore, the precise diagnosis and staging is critical for the
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selection of treatments and improvement of outcome of
the patients with STS.
The clinical staging system is based on the histological
grade of STS. It has been shown that the histological
grade correlates well with prognosis of the patients with
STS [5]. Various histological grading systems of STS
have been proposed. Among them, French Federation of
Cancer Center (FNCLCC) system is one of the most
popular and widely used grading systems [6]. In the
FNCLCC system, histological grading is rated by the
total of the scores for three parameters, including the
tumor differentiation, degree of necrosis, and mitotic
count. However, the mitotic count is affected by various
factors such as the interval between surgical resection
and fixation of tumor tissue, cell size and tumor cellu-
larity, and the experience of the pathologists [7–10], so
the development of more precise and objective grading
system has been required.
Recently, the usefulness of Ki-67 (MIB-1) score has
been reported in some retrospective studies. Using the
retrospective data of 95 patients with STS of the extrem-
ities, trunk, head, and neck treated in the single institu-
tion, we have previously reported the usefulness of a
novel histological grading system based on the three pa-
rameters: tumor differentiation, degree of necrosis, and
Ki-67 (MIB-1) score [7]. In this system, the mitotic
count in FNCLCC system was replaced by cell count in
Ki-67 immunohistochemical staining. We have shown
that the Ki-67 grading system was the most significant
independent prognostic factor for the patients with STS
in the multivariate analysis [11]. We also retrospectively
analyzed validity (sensitivity and specificity) and repro-
ducibility (agreement) of diagnosis of histological grade
using Ki-67 grading and FNCLCC systems for STS by
comparing the independent diagnosis of four patholo-
gists and the gold standard which was diagnosed by two
experts who developed Ki-67 grading system [12]. The
results indicated that the validity and reproducibility of
Ki-67 grading system in the diagnosis of histological
grading of STS was higher than that of FNCLCC system.
We have conducted the phase II clinical trial for
STS, Japan Clinical Oncology Group Study JCOG0304.
In JCOG0304, patients with operable, high-grade STS
in the extremities were treated with perioperative DOX
60 mg/m2 plus IFO 10 g/m2 for three courses with 3-
week interval, followed by operation and postoperative
two courses of the same regimen [13, 14]. To further
evaluate the validity and reproducibility of Ki-67 grad-
ing system in prospective study, we compared Ki-67
grading system with FNCLCC system using the clinical
data of the patients in JCOG0304. We also analyzed
the factors including both Ki-67 and FNCLCC grades




Records of 72 patients with STS enrolled in JCOG0304
trial conducted by JCOG Bone and Soft Tissue Tumor
Study Group (JCOG-BSTTSG) were used in the present
study. Details of eligibility criteria in JCOG0304 have been
stated elsewhere [14]. Key inclusion criteria of the trial
was as follows: (1) a histological diagnosis of STS as undif-
ferentiated pleomorphic sarcoma, fibrosarcoma, leiomyo-
sarcoma, synovial sarcoma, liposarcoma, pleomorphic
rhabdomyosarcoma, or undifferentiated sarcoma using
open biopsy specimen; (2) FNCLCC histological grading
system: grade 2 or 3; (3) AJCC/UICC (6th edition) stage
III (T2bN0M0); (4) resectable tumor in the extremities;
(5) measurable lesion on magnetic resonance imaging
(MRI) axial section; (6) age between 20 and 70 years; (7)
Eastern Cooperative Oncology Group (ECOG) perform-
ance status 0 or 1; and (8) sufficient organ function.
The patients were treated with preoperative chemo-
therapy consisted of DOX (30 mg/m2/day, days 1 and 2)
and IFO (2 g/m2/day, days 1 to 5), and was repeated for
three courses every 3 weeks. The tumor was resected
within 5 weeks of the last course of preoperative chemo-
therapy. When the tumor resection was completed, two
courses of the same regimen as preoperative chemother-
apy with DOX and IFO were carried out every 3 weeks.
No additional therapy was given until the patient exhib-
ited treatment failure including local recurrence and/or
distant metastasis.
The study protocol was approved by the Clinical Trial
Review Committee of JCOG, and also approved by the
Institutional Review Boards of each of the 27 participat-
ing institutes. All patients gave written informed consent
before entry to the study.
Pathological central review
Histological diagnosis and grading of the biopsy samples
from all patients in the present study were reviewed by
the Central Pathological Committee of JCOG-BSTTSG.
To obtain enough amounts of tumors, all samples were
collected by open biopsy. Needle biopsy was not allowed
in the present study. The committee consisted of three
pathologists specialized in diagnosis of STS from three
institutions (TH, YO, and TN). The review was inde-
pendently performed by each pathologist; then, the con-
sensus diagnosis of the tumor was determined by the
committee meeting.
Ki-67 immunostaining was carried out by the Central
Pathological Committee for the grading of all tumor
samples as previously described [7]. Briefly, 4-μm-thick
sections were stained with antibodies for Ki-67 (clone:
MIB-1, 1:100 dilution, DAKO, Tokyo, Japan). The sections
were subjected to heat-induced epitope unmasking with
Target Retrieval Solution (pH 9, DAKO) using microwave
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for 20 min. Ki-67 score was assessed by counting the per-
centages of Ki-67-positive nuclei per 1000 tumor cells in
the region of the tumor with the greater density of stain-
ing, which usually corresponded to the areas with the
highest mitotic activity in the tumor. The histologic grade
was calculated by adding scores of three factors; tumor
differentiation, tumor necrosis, and Ki-67 immunostain-
ing, each of which was given a score of 0 to 3. Thus, in
this system, the mitotic count in FNCLCC system was
simply replaced by cell count in Ki-67 immunostaining. A
Ki-67 score of 1 was assigned to lesions with 0–9 % of the
tumor cells positive for Ki-67 immunostaining, a score of
2 was those with 10–29 %, and a score of 3 was those
with ≥30 % of the tumor cells positive for Ki-67 immu-
nostaining, respectively. The standard FNCLCC grading
system was also used in this study.
Data management and treatment evaluation
The JCOG Data Center performed data management and
statistical analysis. The center also performed central
monitoring to ensure data submission, patient eligibility,
protocol compliance, safety, and on-schedule study pro-
gress. None of the orthopedic surgeons who performed
the protocol treatment were involved in the data analysis.
Statistical method
As a measure of reproducibility, weighted kappa statis-
tics (κ) with Cicchetti-Allison weight type [15] in each
pair of the three pathologists, i.e., three combinations,
was calculated both for FNCLCC and Ki-67 grading sys-
tems. Confidence interval of weighted kappa statistics
for overall agreement between pairs of the pathologists
was estimated by bootstrap sampling method [16]. As a
measure of agreement and reproducibility, κ value is
commonly interpreted as follows: 0.00–0.20, slight;
0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80, substan-
tial; and 0.81–1.00, almost perfect agreement [17].
Overall survival (OS) was defined as the time from en-
rollment to death and censored at the date of last con-
tact for a surviving patient. The overall survival was
estimated by Kaplan-Meier method.
Univariate and multivariate Cox regression analysis was
performed to investigate the impact on overall survival.
Hazard ratios and p values were derived by Cox regression
model. The following factors were investigated: age, sex,
ECOG performance status, tumor location, tumor size,
histological subtype, tumor differentiation score, tumor
necrosis score, tumor mitosis score, histological grade
assessed by FNCLCC system, and histological grade
assessed by Ki-67 grading system. Of these, data retrieved
by institutional decision was used only for univariate ana-
lysis, while the data reviewed by the Central Pathological
Committee was used both for univariate and multivariate
analyses. As a sensitivity analysis, multivariate analysis
with backward elimination method with alpha of 0.2 was
also performed. Statistical analysis was done with SAS ver-
sion 9.1 or more (SAS Institute, Cary, NC).
Results
Patient characteristics
From March 2004 to September 2008, a total of 72 patients
were enrolled into the JCOG0304 trial, and 70 eligible pa-
tients in the trial were included in the present analysis.
The characteristics of the patients were as follows.
Briefly, 36 patients were male and 34 patients were fe-
male, and the median age of patients was 48.5 years old
(range 21–66 years). Tumor location included the
thigh in 34 patients, the calf in 9 patients, the other
sites of the lower extremity in 14 patients, the shoulder
in 6 patients, the upper arm in 2 patients, the forearm
in 1 patient, and the other sites of the upper extremity
in 4 patients. The median tumor size was 7.45 cm. The
histological diagnosis of tumors by institutional deci-
sion was as follows: synovial sarcoma in 20 patients,
undifferentiated pleomorphic sarcoma in 17 patients,
leiomyosarcoma in 11 patients, fibrosarcoma in 5 pa-
tients, liposarcoma in 4 patients, undifferentiated sar-
coma in 4 patients, pleomorphic rhabdomyosarcoma
in 2 patients, and other histological subtype in 7
patients.
Histological grading using Ki-67 and mitosis
Among 70 tumors, according to the grading system
using mitosis, 36 and 34 tumors were assessed as grade
2 and grade 3, respectively, by the Pathological Central
Committee. On the other hand, with the grading system
using Ki-67 immunostaining, 32 and 38 tumors were
assessed as grade 2 and grade 3, respectively (Table 1).
Seven tumors assessed as grade 2 using mitosis were
evaluated as grade 3 using Ki-67, whereas three tumors
assessed as grade 3 using mitosis were evaluated grade 2
using Ki-67, respectively. The distribution of Ki-67 im-
munostaining ranged from 1 to 90 % (median 25 %)
(Fig. 1). The distribution pattern was similar to that in
the previous report [17].
Next, the reproducibility of each grading system was
evaluated. Of 70 tumors, 67 tumors were evaluated for
the analysis of the reproducibility. The agreement
between pathologist 1 and 2, 1 and 3, and 2 and 3 for
Table 1 Histological grading by Ki-67 immunostaining and mitotic
count (n= 70)
Grade using Ki-67
Grade 2 Grade 3 Total
Grading using mitosis Grade 2 29 7 36
Grade 3 3 31 34
Total 32 38 70
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Ki-67 immunostaining was κ = 0.65 (95 % CI 0.47–0.83),
0.54 (95 % CI 0.34–0.73), and 0.41 (95 % CI 0.20–
0.61), respectively (Table 2). On the other hand, the
agreement between pathologist 1 and 2, 1 and 3, and 2
and 3 for mitosis was κ = 0.45 (95 % CI 0.26–0.65),
0.47 (95 % CI 0.27–0.67), and 0.47 (95 % CI 0.26–
0.67), respectively (Table 3). Taken together, the overall
agreement between pairs of the pathologists for Ki-67
was κ = 0.54 (95 % CI 0.39–0.71), and for mitosis was
κ = 0.46 (95 % CI 0.32–0.62).
Prognostic factors
With a median follow-up of 3.6 years for 70 eligible pa-
tients included in this study, the proportion of 2-year
and 5-year OS for the included patients in the present
analysis (n = 70) was 91.4 % (95 % CI, 81.9–96.1 %) and
81.8 % (95 % CI, 68.9–89.7 %), respectively. There
were no significant differences in survival regarding
age (<50 vs. ≥50), sex (male vs. female), tumor size
(<10 vs. ≥10 cm, or <8 vs. ≥8 cm), histological subtypes
(UPS vs. synovial sarcoma vs. others), histological tumor
differentiation (score 2 vs. 3), tumor necrosis (score 2 vs.
3), and mitosis (score 1 vs. 2 vs. 3) (Table 4). There was also
no significant difference between survival of the patients
with FNCLCC grade 2 tumors (5-year OS 90.9 %, [95 % CI
74.3–97.0]) and that with grade 3 tumors (5-year OS
73.5 %, [95 % CI 53.2–86.1]) (HR 2.80, 95 % CI 0.74–10.55,
p = 0.13) (Fig. 2). However, survival of the patients with the
tumor assessed as histologic grade 3 by Ki-67 immuno-
staining was worse than that with the tumor assessed as
grade 2. The 5-year OS for grade 3 and grade 2 tumors
using Ki-67 was 73.5 % (95 % CI 54.4–85.6) (n = 38) and
91.8 % (95 % CI 69.8–98.0) (n = 32), respectively (HR 4.12,
95 % CI 0.89–19.09, p = 0.070) (Fig. 3, Table 4). While
FNCLCC grading system was not selected as a prognostic
factor by multivariate analysis with backward elimination,
Ki-67 grading system was also tended to associate with OS
on multivariate analysis with backward elimination (HR
3.51, 95 % CI 0.75–16.36, p = 0.11) (Table 5).
Discussion
In the present study, we investigated the differences in
the diagnosis of the histological grade of STS assessed
Fig. 1 Distribution of Ki-67 immunostaining in JCOG0304 study
Table 2 Reproducibility of grading using Ki-67 (n = 67)
Pathologist 2
Grade 1 Grade 2 Grade 3 Total
Pathologist 1 Grade 1 2 0 0 2
Grade 2 0 22 8 30
Grade 3 0 5 30 35
Total 2 27 38 67
κ = 0.65 (95 % CI 0.47–0.83)
Pathologist 3
Pathologist 1 Grade 1 1 1 0 2
Grade 2 0 25 5 30
Grade 3 0 11 24 35
Total 1 37 29 67
κ = 0.54 (95 % CI 0.34–0.73)
Pathologist 3
Pathologist 2 Grade 1 1 1 0 2
Grade 2 0 21 6 27
Grade 3 0 15 23 38
Total 1 37 29 67
κ = 0.41 (95 % CI 0.20–0.61)
Table 3 Reproducibility of grading using mitosis (n = 67)
Pathologist 2
Grade 1 Grade 2 Grade 3 Total
Pathologist 1 Grade 1 0 1 0 1
Grade 2 2 30 9 41
Grade 3 0 7 18 25
Total 2 38 27 67
κ = 0.45 (95 % CI 0.26–0.65)
Pathologist 3
Pathologist 1 Grade 1 0 1 0 1
Grade 2 2 32 7 41
Grade 3 0 8 17 25
Total 2 41 24 67
κ = 0.47 (95 % CI 0.27–0.67)
Pathologist 3
Pathologist 2 Grade 1 1 1 0 2
Grade 2 1 30 7 38
Grade 3 0 10 17 27
Total 2 41 24 67
κ = 0.47 (95 % CI 0.26–0.67)
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by Ki-67 expression levels and mitosis using the biopsy
samples of STS in JCOG0304. We further analyzed the
impact of prognostic factors including the histological
grade on survival of the patients with STS in the clinical
trial. The results demonstrated that there was the sub-
stantial disagreement (14.3 %) between Ki-67 grading
system and FNCLCC system, and that Ki-67 grading sys-
tem might exhibit better reproducibility in the assess-
ment of histological grading of STS in the extremities
than mitotic score. Potential prognostic value of Ki-67
has also been shown.
We have previously demonstrated that the grading sys-
tem using Ki-67 immunostaining was better in terms of
the validity and reproducibility than FNCLCC system
using mitotic score [12]. We have also indicated that the
Ki-67 grading system was significantly associated with
the prognosis of the patients with STS in the multivari-
ate analysis [11]. However, those reports were retro-
spective analyses from a single institution. Therefore, we
investigated the validity and reproducibility of the Ki-67
grading system in the grading of STS treated by the
same regimen in the multi-institutional clinical trial,
JCOG0304 [13, 14].
In the present study, the histological grade of 10
tumors among 70 (14.3 %) showed disconcordance be-
tween FNCLCC system and Ki-67 grading system, indi-
cating that the disagreement between both systems was
not negligible. Thus, the reproducibility was calculated
as kappa statistics to elucidate which system would be
better. The averaged weighted kappa statistics between
pairs of three expert pathologists for Ki-67 was κ = 0.54
(95 % CI 0.39–0.71), and for mitosis was κ = 0.46 (95 % CI
0.32–0.62). In the retrospective study, the κ score was 0.61
for Ki-67 immunostaining and 0.54 for mitotic score, sug-
gesting the superiority of Ki-67 grading system to
FNCLCC system [9]. It was also reported that the κ
statistics using mitosis of FNCLCC system was 0.38
for FNCLCC grade 2 and 0.48 for grade 3 tumors, re-
spectively [18]. The possible reason for the better re-
producibility of Ki-67 grading system over FNCLCC
system is that Ki-67 is expressed in all phases of the
cycle except G0 and is a better measure of dividing
cells than HE staining [19]. Our results were consist-
ent with those in the previous reports, and demon-
strating that Ki-67 grading system is also valid in the
prospective study. On the other hand, Ki-67 grading
Table 4 Univariate analysis for survival
Factors Category Univariate analysis HR
(95 % CI) p value
Sex Female (vs. male) 0.89 (0.27–2.93) 0.85
Age (years) ≥40 (vs. <40) 5.12 (0.65–40.06) 0.12
Performance status 1 (vs. 0) 0.59 (0.13–2.72) 0.50
Histological subtype Leiomyosarcoma (vs. UPS) 0.39 (0.04–3.51) 0.40
Synovial sarcoma (vs. UPS) 0.69 (0.15–3.08) 0.63
Others (vs. UPS) 0.64 (0.14–2.87) 0.56
Tumor differentiation 3 (vs. 2) 0.71 (0.22–2.31) 0.56
Tumor necrosis 1 or 2 (vs. 0) 2.96 (0.64–13.73) 0.16
Tumor mitosis 2 or 3 (vs. 1) 1.28 (0.37–4.36) 0.70
Histological grade (FNCLCC) Grade 3 (vs. 2) 2.80 (0.74–10.55) 0.13
Histological grade (Ki-67) Grade 3 (vs. 2) 4.12 (0.89–19.09) 0.070
Fig. 2 Kaplan-Meier estimates of overall survival by FNCLCC
grading (n = 70)
Fig. 3 Kaplan-Meier estimates of overall survival by Ki-67
grading (n = 70)
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system depends on the immunoreactivity of Ki-67
antigen in the tumor specimens. Thus, the results of
Ki-67 scoring might be affected by various factors dur-
ing immunohistochemical study including fixation time
and evaluation methods. To minimize the influence of
these factors on Ki-67 immunostaining, we standardized
the immunohistochemical procedure and all staining were
carried out only in one institute (Kyushu University).
However, there is a possibility that the results of the
present study might be affected by the variation of Ki-67
immunostaining among specimens.
The results in the present study also exhibited a sub-
stantial disagreement of tumor grading using Ki-67 and
mitosis. It has been reported that overall percent agree-
ment of Ki-67 and mitosis grading among four patholo-
gists was reported to be 79 % (95 % CI, 76–83) and 69 %
(95 % CI, 65–73) [12]. These observations demonstrated
an obvious limitation in the current method for assess-
ment of tumor grading even with Ki-67 system by man-
ual counting of Ki-67 immunostaining. Further
improvement such as measurement by a digital image
analysis system for Ki-67 assessment should be needed
to overcome the difficulties in correct evaluation of
histological grade of STS.
Regarding the prognostic relevance, there was a ten-
dency that the Ki-67 grading system was the potential
prognostic factor associated with OS of the patients in
the present study. However, the difference of OS in the
present study was smaller than that in the previous re-
port [11]. One of the possible reasons for this discrep-
ancy is that the outcome of JCOG0304 was far better
than expected. An Italian randomized study for STS in
the extremities has demonstrated that 4-year OS of the
patients treated by adjuvant chemotherapy with epirubi-
cin plus IFO was 69 % (95 % CI, 68.9–89.7 %) [20]. On
the other hand, 5-year OS for eligible patients was
81.8 % in JCOG0304. Furthermore, our retrospective
study has been reported that 5-year OS for grade 2 and
grade 3 STS was 71.8 and 44.3 %, respectively [11]. In
JCOG0304, 5-year OS for grade 2 and grade 3 STS was
91.8 and 73.5 %, respectively. The results suggested that
the prognosis of the patients with STS in JCOG0304 was
remarkably improved by the intensive pre- and postop-
erative chemotherapy with DOX and IFO. The survival
of the patients with grade 3 tumors in the present study
was comparable to that with grade 2 tumors in the pre-
vious report. The high survival rate of the patients with
grade 3 tumors in this trial might be one of the reasons
why the difference of the survival between grade 2 and
grade 3 tumors was not statistically significant. Since the
trial was phase II study, JCOG0304 had selection biases
including many patients with good prognosis histologic
subtypes of the tumors, and the majority of grade 2
tumor in FNCLCC grading (47 patients out of 72). Thus,
there is a possibility that these imbalanced factors might
have affected to the results of the present study.
Table 5 Multivariate analysis for survival
Factors Category Multivariate analysis (including all variables) HR (95 % CI)
p value
Sex Female (vs. male) 1.75 (0.49–6.30) 0.39
Age (years) ≥40 (vs. <40) 8.25 (0.85–79.91) 0.069
Performance status 1 (vs. 0) 0.60 (0.12–2.95) 0.53
Histological subtype Leiomyosarcoma (vs. UPS) 0.29 (0.03–2.85) 0.29
Synovial sarcoma (vs. UPS) 1.42 (0.27–7.47) 0.68
Others (vs. UPS) 0.55 (0.12–2.60) 0.45
Histological grade (FNCLCC) Grade 3 (vs. 2) 2.24 (0.35–14.30) 0.39
Histological grade (Ki-67) Grade 3 (vs. 2) 2.79 (0.32–24.41) 0.35
Factors Category Multivariate analysis (backward elimination with alpha = 20 %) HR (95 % CI)
p value
Sex Female (vs. male)
Age (years) ≥40 (vs. <40) 4.21 (0.53–33.28) 0.17
Performance status 1 (vs. 0)
Histological subtype Leiomyosarcoma (vs. UPS)
Synovial sarcoma (vs. UPS)
Others (vs. UPS)
Histological grade (FNCLCC) Grade 3 (vs. 2)
Histological grade (Ki-67) Grade 3 (vs. 2) 3.51 (0.75–16.36) 0.11
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In summary, it is suggested that Ki-67 grading system
might show better reproducibility and validity in the as-
sessment of histological grade for STS in the extremities
than FNCLCC system. Furthermore, among factors
tested in the present study, there was a tendency that
Ki-67 grading system was associated with survival in
univariate analysis. Ki-67 grade was also suggested as a
candidate of prognostic factor in multivariate analysis
with backward elimination.
Conclusions
This is the first report demonstrating the efficacy of Ki-67
grading system for the patients with STS in the prospective
trial. The results indicate that Ki-67 grading system might
be useful for the evaluation of histological grade of STS.
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